Australia markets closed
  • ALL ORDS

    7,552.10
    -40.60 (-0.53%)
     
  • AUD/USD

    0.7585
    +0.0031 (+0.41%)
     
  • ASX 200

    7,298.50
    -43.70 (-0.60%)
     
  • OIL

    73.43
    +0.58 (+0.80%)
     
  • GOLD

    1,784.10
    +6.70 (+0.38%)
     
  • BTC-AUD

    44,930.54
    +2,909.11 (+6.92%)
     
  • CMC Crypto 200

    813.96
    +19.63 (+2.47%)
     

Global Gastrointestinal Therapeutics Market Report 2021-2027: Ulcerative Colitis, Crohn's Disease, GERD, Others - ResearchAndMarkets.com

·4-min read

The "Gastrointestinal Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Gastrointestinal Therapeutics Market to Reach $66.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Gastrointestinal Therapeutics estimated at US$52.7 Billion in the year 2020, is projected to reach a revised size of US$66.4 Billion by 2027, growing at a CAGR of 3.4% over the analysis period 2020-2027. Ulcerative Colitis, one of the segments analyzed in the report, is projected to record a 4% CAGR and reach US$12.2 Billion by the end of the analysis period.

The U.S. Market is Estimated at $14.2 Billion, While China is Forecast to Grow at 6.2% CAGR

The Gastrointestinal Therapeutics market in the U.S. is estimated at US$14.2 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$13.8 Billion by the year 2027 trailing a CAGR of 6.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 2.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

GERD Segment to Record 3.8% CAGR

In the global GERD segment, USA, Canada, Japan, China and Europe will drive the 3.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$4.4 Billion in the year 2020 will reach a projected size of US$5.5 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$9.3 Billion by the year 2027, while Latin America will expand at a 4.7% CAGR through the analysis period.

Select Competitors (Total 44 Featured):

  • AbbVie, Inc.

  • Alfa Wassermann, Inc.

  • Allergan PLC

  • Amgen, Inc.

  • Anterogen Co., Ltd.

  • Ardelyx, Inc.

  • Astellas Pharma, Inc.

  • Astellas Pharma, Inc.

  • AstraZeneca PLC

  • Biogen, Inc.

  • Celgene Corporation

  • Cosmo Pharmaceuticals NV

  • Drais Pharmaceuticals, Inc.

  • Eisai Co., Ltd.

  • Eli Lilly and Company

  • Enlivex Therapeutics ltd.

  • F. Hoffmann-La Roche AG

  • Ferring Pharmaceuticals, Inc.

  • FF Pharma

  • Galapagos NV

  • Gilead Sciences, Inc.

  • GlaxoSmithKline, Inc.

  • Hutchison MediPharma Limited

  • Immune Pharmaceuticals, Inc.

  • InDex Pharmaceuticals Holding AB

  • Ironwood Pharmaceuticals, Inc.

  • Johnson & Johnson

  • Kissei Pharmaceutical Co., Ltd.

  • Kyowa Hakko Kirin Co., Ltd.

  • Lexicon Pharmaceuticals, Inc.

  • Lipid Therapeutics GmbH

  • Meda AB

  • Merck & Co., Inc.

  • Mesoblast Ltd.

  • Mitsubishi Tanabe Pharma Corporation

  • Mochida Pharmaceutical Co., Ltd.

  • Morphotek, Inc.

  • Neovacs S.A.

  • Nestle SA

  • Norgine BV

  • Novartis AG

  • Pfizer, Inc.

  • Procter & Gamble Company, The

  • Qu Biologics Inc.

  • RedHill Biopharma Ltd.

  • Sterna Biologicals GmbH & Co. KG

  • Synthetic Biologics, Inc.

  • Takeda Pharmaceutical Co., Ltd.

  • TiGenix NV

  • Tillotts Pharma AG

  • TopiVert Ltd.

  • UCB SA

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • Influencer Market Insights

  • World Market Trajectories

  • Impact of Covid-19 and a Looming Global Recession

  • World 15-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Ulcerative Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Crohn's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

  • World 15-Year Perspective for GERD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. GEOGRAPHIC MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 44

For more information about this report visit https://www.researchandmarkets.com/r/hii645

View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005551/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting